Key Performance Indicators for the financial year 2025-26
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anthem Biosciences disclosed strong financial performance for FY 2025-26 with total revenue of ₹21,243 million, representing 15.17% year-on-year growth. The company reported EBITDA of ₹8,972 million (up 31.21%) with a healthy EBITDA margin of 47.07%, and PAT of ₹5,918 million (up 31.14%) with PAT margin of 25.95%. Revenue split shows 83% from CRDMO services (Contract Research, Development & Manufacturing Operations) and 17% from Specialty Ingredients. The company maintains a strong net cash position of ₹13,744 million with net cash to EBITDA ratio of 1.53x. Operational metrics show 2,282 employees including 1,117 scientific staff, and revenue per employee improved to ₹9.31 million. Material margin stands at 61.76%, while ROE is 21.71% and post-tax ROCE is 30.78%.
The company delivered robust double-digit growth across all profitability metrics with margin expansion, indicating operational efficiency improvements. Strong cash generation and low leverage provide flexibility for future growth investments. The consistent shift toward higher-margin CRDMO services is a positive structural trend.